Animalcare Group plc has received a positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP) recommending a marketing authorisation for Daxocox (enflicoxib) in Europe. Daxocox is a novel COX 2 inhibitor and was filed for approval in January 2020 for the treatment of pain and inflammation associated with osteoarthritis (or degenerative joint disease) in dogs. Following the CVMP's positive opinion, a marketing authorisation decision from the European Commission is anticipated early in the second quarter of 2021. If approved, the authorisation will be valid in all member states of the European Union as well as Norway, Liechtenstein and Iceland. The equivalent regulatory review of Daxocox for the UK is running largely in parallel with the European Union's schedule and the Group expects a decision on UK marketing authorisation within the same timeframe. The development programme for Daxocox is led and managed by the Animalcare team under the pipeline project name, E-6087. Daxocox is the sole property of Animalcare Group plc.